Background Despite the availability of safe and efficacious coronavirus disease 2019
vaccines, a significant proportion of the American public remains unvaccinated and does not …

Background Case detection underestimates the burden of the COVID‐19 pandemic. Following
the first COVID‐19 wave, we estimated the seroprevalence of severe acute respiratory …

Hepatitis C virus (HCV) has emerged as one of the most vexing health problems facing HIV-infected
persons. Due largely to injection drug use (IDU),> 30% of HIV-infected patients are …

Background: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens
are costly. This presents challenges for universal drug coverage of the estimated 220 …

Co‐infection of HCV with HIV has been associated with more rapid progression of HCV‐related
disease. HCV‐specific T‐cell immune responses, which are essential for disease control…

Background. Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) have been
described as revolutionary. However, it remains uncertain how effective these drugs will be for …

Objective: HIV is known to have a negative impact on the progression of hepatitis C virus (HCV)
infection, whereas the reverse remains unclear. We examined the impact of …

… Hull, Brian Conway Drafting of the manuscript: Sahar Saeed; Critical revision of the manuscript
for important intellectual content: Sahar Saeed, Marina Klein, Erin Strumpf, Erica Moodie, …

Background and Aims Direct‐acting antivirals (DAAs) are highly effective in treating hepatitis
C. However, there is concern that cure rates may be lower, and reinfection rates higher, …

Introduction There is currently no published data on the effectiveness of DAA treatment for
elimination of HCV infection in HIV ‐infected populations at a population level. However, a …